Search

N-alkyl ethylbenzyl dimethyl ammonium (C12-C14)

It is found in sanitizing solutions or soaps as an active ingredient due to its antimicrobial properties. … formal mechanism of action of quaternary ammonium compounds like n-alkyl C12-C14 dimethyl ethylbenzyl ammonium chloride is difficult to elucidate.

Milrinone

Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and … [A228338, A11759, A228323, A228333, A228348, L31483] Milrinone was originally synthesized at the Sterling Winthrop Research Institute in the 1980s.

Zanubrutinib

[A187958] Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. … In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia.[L39030] This indication is valid in the US, Europe, and Canada.

Carindacillin

It is no longer marketed in the United States.

Lithium citrate

Miconazole

[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity. … [A214523, L14021] It is currently available as a variety of prescription and over the counter products.

Oveporexton

[L64068,L64069] It is the first orexin receptor agonist approved by the FDA and the first medicine to treat NT1 by targeting its underlying cause rather than individual symptoms. … [L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults.

Menthyl salicylate

This product is used to treat minor aches and pains of the muscles/joints (e.g., arthritis, backache, sprains) [L2810].

Berotralstat

[A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. … [L26661] It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE.

Reslizumab

the first attack compared to patients receiving placebo [FDA Label, A31579]. … Asthma is a chronic respiratory disease that causes inflammation in the lungs with asthma attacks that lead to severe breathing difficulties.